Search Results - "Engle, Melissa"

Effects of Tuberculosis, Race, and Human Gene SLCO1B1 Polymorphisms on Rifampin Concentrations by WEINER, Marc, PELOQUIN, Charles, BURMAN, William, LUO, Chi-Cheng, ENGLE, Melissa, PRIHODA, Thomas J, MAC KENZIE, William R, BLIVEN-SIZEMORE, Erin, JOHNSON, John L, VERNON, Andrew

“…OA  Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley…”
Get full text

Reductions in Symptomatology at a Residential Treatment Center for Substance Use Disorders by Ross, Colin A., Engle, Melissa Caldwell, Baker, Billie

“…The authors hypothesized that their Integrated Addiction Model, a trauma-focused treatment approach at a residential treatment center for substance use…”
Get full text

Aptamer-based proteomic signature of intensive phase treatment response in pulmonary tuberculosis by Nahid, Payam, Bliven-Sizemore, Erin, Jarlsberg, Leah G, De Groote, Mary A, Johnson, John L, Muzanyi, Grace, Engle, Melissa, Weiner, Marc, Janjic, Nebojsa, Sterling, David G, Ochsner, Urs A

“…Summary Background New drug regimens of greater efficacy and shorter duration are needed for tuberculosis (TB) treatment. The identification of accurate,…”
Get full text

Effects of Rifampin and Multidrug Resistance Gene Polymorphism on Concentrations of Moxifloxacin by WEINER, Marc, BURMAN, William, LUO, Chi-Cheng, PELOQUIN, Charles A, ENGLE, Melissa, GOLDBERG, Stefan, AGARWAL, Vipin, VERNON, Andrew

“…Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit…”
Get full text

Evidence for acclimation of N cycling to episodic N inputs in anthropogenically-affected intertidal salt marsh sediments by Aelion, C. Marjorie, Engle, Melissa R.

“…Nitrate removal was compared in anthropogenically-impacted and unimpacted salt marsh sediments in microcosms using the acetylene block technique and 15N…”
Get full text

Evaluation of Time to Detection of Mycobacterium tuberculosis in Broth Culture as a Determinant for End Points in Treatment Trials by Weiner, Marc, Prihoda, Thomas J, Burman, William, Johnson, John L, Goldberg, Stefan, Padayatchi, Nesri, Duran, Paula, Engle, Melissa, Muzanye, Grace, Mugerwa, Roy D, Sturm, A. Willem

“…Time to detection of Mycobacterium tuberculosis in broth culture was examined for utility as a treatment efficacy end point. Of 146 patients in a phase IIB…”
Get full text

Evaluation of the Drug Interaction between Rifabutin and Efavirenz in Patients with HIV Infection and Tuberculosis by Marc, Weiner, Benator, Debra, Peloquin, Charles A., Burman, William, Vernon, Andrew, Engle, Melissa, Khan, Awal, Zhao, Zhen

“…Background. Because of drug-drug interactions mediated by hepatic cytochrome P450, tuberculosis treatment guidelines recommend an increase in rifabutin from…”
Get full text

Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis by Dorman, Susan E, Nahid, Payam, Kurbatova, Ekaterina V, Phillips, Patrick P.J, Bryant, Kia, Dooley, Kelly E, Engle, Melissa, Goldberg, Stefan V, Phan, Ha T.T, Hakim, James, Johnson, John L, Lourens, Madeleine, Martinson, Neil A, Muzanyi, Grace, Narunsky, Kim, Nerette, Sandy, Nguyen, Nhung V, Pham, Thuong H, Pierre, Samuel, Purfield, Anne E, Samaneka, Wadzanai, Savic, Radojka M, Sanne, Ian, Scott, Nigel A, Shenje, Justin, Sizemore, Erin, Vernon, Andrew, Waja, Ziyaad, Weiner, Marc, Swindells, Susan, Chaisson, Richard E

“…In this phase 3 trial for the treatment of tuberculosis, a 4-month rifapentine-based regimen containing moxifloxacin was noninferior to a standard 6-month…”
Get full text

Use of ^(15)N Natural Abundance and N Species Concentrations to Assess N-Cycling in Constructed and Natural Coastal Wetlands by Aelion, C. Marjorie, Engle, Melissa R., Ma, Hongbo

“…Natural abundance of N stable isotopes used in combination with concentrations may be useful indicators of N-cycling in wetlands. Concentrations and N…”
Get full text

Pyrazinamide Safety, Efficacy, and Dosing for Treating Drug-Susceptible Pulmonary Tuberculosis: A Phase 3, Randomized, Controlled Clinical Trial by Xu, Ava Y, Velásquez, Gustavo E, Zhang, Nan, Chang, Vincent K, Phillips, Patrick Pj, Nahid, Payam, Dorman, Susan E, Kurbatova, Ekaterina V, Whitworth, William C, Sizemore, Erin, Bryant, Kia, Carr, Wendy, Brown, Nicole E, Engle, Melissa L, Nhung, Nguyen Viet, Nsubuga, Pheona, Diacon, Andreas, Dooley, Kelly E, Chaisson, Richard E, Swindells, Susan, Savic, Radojka M

“…Optimizing pyrazinamide dosing is critical to improve treatment efficacy while minimizing toxicity during tuberculosis treatment. Study 31/ACTG A5349…”
Get full text

Pharmacokinetic-Pharmacodynamic Evidence From a Phase 3 Trial to Support Flat-Dosing of Rifampicin for Tuberculosis by Ngo, Huy X, Xu, Ava Y, Velásquez, Gustavo E, Zhang, Nan, Chang, Vincent K, Kurbatova, Ekaterina V, Whitworth, William C, Sizemore, Erin, Bryant, Kia, Carr, Wendy, Weiner, Marc, Dooley, Kelly E, Engle, Melissa, Dorman, Susan E, Nahid, Payam, Swindells, Susan, Chaisson, Richard E, Nsubuga, Pheona, Lourens, Madeleine, Dawson, Rodney, Savic, Radojka M

“…Abstract Background The optimal dosing strategy for rifampicin in treating drug-susceptible tuberculosis (TB) is still highly debated. In the phase 3 clinical…”
Get full text

Decreased plasma rifapentine concentrations associated with AADAC single nucleotide polymorphism in adults with tuberculosis by Weiner, Marc, Gelfond, Jon, Johnson-Pais, Teresa L, Engle, Melissa, Johnson, John L, Whitworth, William C, Bliven-Sizemore, Erin, Nsubuga, Pheona, Dorman, Susan E, Savic, Rada

“…Abstract Background Rifapentine exposure is associated with bactericidal activity against Mycobacterium tuberculosis, but high interindividual variation in…”
Get full text

Risk-stratified treatment for drug-susceptible pulmonary tuberculosis by Chang, Vincent K., Imperial, Marjorie Z., Phillips, Patrick P. J., Velásquez, Gustavo E., Nahid, Payam, Vernon, Andrew, Kurbatova, Ekaterina V., Swindells, Susan, Chaisson, Richard E., Dorman, Susan E., Johnson, John L., Weiner, Marc, Sizemore, Erin E., Whitworth, William, Carr, Wendy, Bryant, Kia E., Burton, Deron, Dooley, Kelly E., Engle, Melissa, Nsubuga, Pheona, Diacon, Andreas H., Nhung, Nguyen Viet, Dawson, Rodney, Savic, Radojka M.

“…The Phase 3 randomized controlled trial, TBTC Study 31/ACTG A5349 (NCT02410772) demonstrated that a 4-month rifapentine-moxifloxacin regimen for…”
Get full text

Elevated Plasma Moxifloxacin Concentrations and SLCO1B1 g.-11187G>A Polymorphism in Adults with Pulmonary Tuberculosis by Weiner, Marc, Gelfond, Jon, Johnson-Pais, Teresa L, Engle, Melissa, Peloquin, Charles A, Johnson, John L, Sizemore, Erin E, Mac Kenzie, William R

“…Moxifloxacin exhibits concentration-dependent prolongation of human QTc intervals and bactericidal activity against However, moxifloxacin plasma concentrations…”
Get full text

Substitution of Moxifloxacin for Isoniazid during Intensive Phase Treatment of Pulmonary Tuberculosis by Dorman, Susan E, Johnson, John L, Goldberg, Stefan, Muzanye, Grace, Padayatchi, Nesri, Bozeman, Lorna, Heilig, Charles M, Bernardo, John, Choudhri, Shurjeel, Grosset, Jacques H, Guy, Elizabeth, Guyadeen, Priya, Leus, Maria Corazon, Maltas, Gina, Menzies, Dick, Nuermberger, Eric L, Villarino, Margarita, Vernon, Andrew, Chaisson, Richard E, Tuberculosis Trials Consortium

“…Moxifloxacin has potent activity against Mycobacterium tuberculosis in vitro and in a mouse model of antituberculosis (TB) chemotherapy, but data regarding its…”
Get full text

Moxifloxacin versus Ethambutol in the First 2 Months of Treatment for Pulmonary Tuberculosis by Burman, William J, Goldberg, Stefan, Johnson, John L, Muzanye, Grace, Engle, Melissa, Mosher, Ann W, Choudhri, Shurjeel, Daley, Charles L, Munsiff, Sonal S, Zhao, Zhen, Vernon, Andrew, Chaisson, Richard E, and Tuberculosis Trials Consortium

“…Moxifloxacin has promising preclinical activity against Mycobacterium tuberculosis, but has not been evaluated in multidrug treatment of tuberculosis in…”
Get full text

Blood Transcriptional Biomarkers for Active Tuberculosis among Patients in the United States: a Case-Control Study with Systematic Cross-Classifier Evaluation by Walter, Nicholas D, Miller, Mikaela A, Vasquez, Joshua, Weiner, Marc, Chapman, Adam, Engle, Melissa, Higgins, Michael, Quinones, Amy M, Rosselli, Vanessa, Canono, Elizabeth, Yoon, Christina, Cattamanchi, Adithya, Davis, J Lucian, Phang, Tzu, Stearman, Robert S, Datta, Gargi, Garcia, Benjamin J, Daley, Charles L, Strong, Michael, Kechris, Katerina, Fingerlin, Tasha E, Reves, Randall, Geraci, Mark W

“…Blood transcriptional signatures are promising for tuberculosis (TB) diagnosis but have not been evaluated among U.S. To be used clinically, transcriptional…”
Get full text

Pharmacokinetic interaction of rifapentine and raltegravir in healthy volunteers by Weiner, Marc, Egelund, Eric F., Engle, Melissa, Kiser, Melissa, Prihoda, Thomas J., Gelfond, Jonathan A. L., Mac Kenzie, William, Peloquin, Charles A.

“…Objectives Latent tuberculosis infection and tuberculosis disease are prevalent worldwide. However, antimycobacterial rifamycins have drug interactions with…”
Get full text

High-dose rifapentine with or without moxifloxacin for shortening treatment of pulmonary tuberculosis: Study protocol for TBTC study 31/ACTG A5349 phase 3 clinical trial by Dorman, Susan E., Nahid, Payam, Kurbatova, Ekaterina V., Goldberg, Stefan V., Bozeman, Lorna, Burman, William J., Chang, Kwok-Chiu, Chen, Michael, Cotton, Mark, Dooley, Kelly E., Engle, Melissa, Feng, Pei-Jean, Fletcher, Courtney V., Ha, Phan, Heilig, Charles M., Johnson, John L., Lessem, Erica, Metchock, Beverly, Miro, Jose M., Nhung, Nguyen Viet, Pettit, April C., Phillips, Patrick P.J., Podany, Anthony T., Purfield, Anne E., Robergeau, Kathleen, Samaneka, Wadzanai, Scott, Nigel A., Sizemore, Erin, Vernon, Andrew, Weiner, Marc, Swindells, Susan, Chaisson, Richard E.

“…Phase 2 clinical trials of tuberculosis treatment have shown that once-daily regimens in which rifampin is replaced by high dose rifapentine have potent…”
Get full text

Central monitoring in a randomized, open-label, controlled phase 3 clinical trial for a treatment-shortening regimen for pulmonary tuberculosis by Bryant, Kia E., Yuan, Yan, Engle, Melissa, Kurbatova, Ekaterina V., Allen-Blige, Cynthia, Batra, Kumar, Brown, Nicole E., Chiu, Kuo wei, Davis, Howard, Elskamp, Mascha, Fagley, Melissa, Fedrick, Pamela, Hedges, Kimberley N.C., Narunsky, Kim, Nassali, Joanita, Phan, Mimi, Phan, Ha, Purfield, Anne E., Ricaldi, Jessica N., Robergeau-Hunt, Kathleen, Whitworth, William C., Sizemore, Erin E.

“…With the growing use of online study management systems and rapid availability of data, timely data review and quality assessments are necessary to ensure…”
Get full text